Abstract: Disclosed are perfume compositions containing perfume ingredients selected on the basis that they are able to be stably incorporated into core-shell microcapsules. Perfume selection rules are based on a molecular descriptor of the electron density distribution within a perfume ingredient—RECON VOLTAE. Perfume ingredients having known RECON_VOLTAE values larger than about 1200 Bohr3, more particularly larger than 1540 Bohr3, and more particularly still larger than about 1750 Bohr3 are particularly suitable for encapsulation.

Abstract: The present invention is directed to a method of achieving improved hair volume comprising applying to hair a composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 1500 and mixtures thereof or, by weight of said hair care composition; wherein an emulsifier is selected from the group consisting of anionic, non-ionic, cationic, amphoteric and mixtures thereof wherein the average particle size of the pre-emulsified emulsion is from about 20 nanometers to 20 microns; from about 5% to about 50% of one or more anionic surfactants, by weight of said hair care composition; from about 0.

Abstract: The present invention relates to cosmetic or dermatological compositions containing PQQ or its esters, methods of treating or promoting skin changes by topical application of these compositions, and methods of synthesis of PQQ esters. The PQQ ester-containing compositions of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the PQQ esters of the present invention have an antioxidant effect that is useful in treating a skin change.

Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Abstract: A lotion emulsion composition comprising a preservative enhancing agent and a rheology modifier, wherein the preservative enhancing agent comprises one of sorbitan caprylate, glyceryl caprylate/caprate, or a combination thereof, the rheology modifier comprises a hydrocolloid, the pH of the lotion emulsion composition is less than about 4.2, and the combined amount of preservative enhancing agent and rheology modifier is less than about 0.3% by weight of the total lotion emulsion composition.

Abstract: The present invention relates to a two-compartment aerosol device, comprising a styling composition in a first compartment and a compressed gas chosen from air, nitrogen and carbon dioxide, and mixtures thereof, in a second compartment. Said styling composition comprises at least one compound (A) chosen from an anionic carboxylic polymer free of urethane units, a linear sulfonic polyester and a cellulose-based compound in an alcoholic or aqueous-alcoholic medium which comprises at least 5% by weight, relative to the weight of said composition, of a C1-C4 monohydric alcohol. This aerosol device may constitute a hair lacquer. The invention also relates to a styling process using the device of the invention.

Abstract: The present invention provides a transdermal delivery system, which comprises a drug-containing matrix layer comprising: galantamine or its pharmaceutically acceptable salt as an active ingredient; and a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.

Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.

Abstract: The present disclosure relates to a sprayable gel composition for hair conditioning, comprising (a) from about 0.01% to about 0.35% by weight of an acrylate/alkyl-acrylate cross-polymer, (b) from about 0.1% to about 30% by weight of a silicone oil selected from dimethylpolysiloxane, cyclic polysiloxanes, hydroxyl-terminated polydimethylsiloxanes, polysiloxane-polyalkylene copolymers, alkyl methyl polysiloxanes, phenylmethylpolysiloxane, hydroxyl-terminated polydimethylsiloxanes, divinyldimethicone/dimethicone copolymer, and combination thereof, (c) from about 0.1% to about 30% by weight of a monohydric alcohol containing from about 2 to about 8 carbon atoms, and (d) from about 40% to about 99.

Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Abstract: The present invention relates in general to a medical device consisting of a blocker made of a mixture of natural products such as African palm oil and the triglycerides thereof and natural waxes as active and emulsifying components, polymer and silver nanoparticles, acting as a blocker for latex protein and other skin irritants.

Abstract: The present disclosure is broadly concerned with petrolatum-based compositions as a suspension matrix for the active ingredients. The disclosure is also concerned with processes for forming stable emulsions of active ingredients in petrolatum.

Abstract: Described herein are aqueous oral care compositions comprising (a) an effective amount of a basic amino acid in free or orally acceptable salt form; and (b) a polymer system comprising (i) a cellulosic polymer, (ii) a gum polymer, and (iii) a polyacrylate polymer or co-polymer; and methods of making and using the same.

Abstract: The present disclosure relates to a sprayable gel composition, comprising (a) from about 0.08% to about 1.8% by weight of a polysaccharide, (b) from about 0.002% to about 0.08% by weight of a divalent alkaline earth cation, (c) from about 0.1% to about 30% by weight of a humectant, (d) from 0% to about 30% by weight of an emollient, and (e) from about 40% to about 95% by weight of a cosmetically acceptable carrier, wherein the weight percentages are based on the total weight of all components of the sprayable gel composition, and to a method of treating hair in need of a conditioning treatment.

Abstract: Functional ingredients including an esterified component and microencapsulated in an enteric matrix to increase the microencapsulation efficiency and reduce undesired organoleptic properties of the microencapsulated material while providing a desired release rate and ester hydrolysis rate, the process including forming an emulsion in water and titrating the emulsion with a precipitating agent to produce a particulate precipitate.

Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.

Abstract: A medical device comprising a composition comprising a therapeutically active amount of active agent, a zinc compound, and an array of microneedles. The zinc compound may be selected from the group consisting of zinc, pharmaceutically acceptable salts of zinc, and mixtures thereof. At least a portion of the composition is present as a coating on at least a portion of the microneedles. Methods of delivering a therapeutically active agent to a mammal using compositions of the disclosure are also included.

Abstract: A non-irritation, non-blurring, photostable ophthalmic sunscreen composition contains at least one of the following: bemotrizinol; bisoctrizole; tris-biphenyl triazine; and/or octyl methoxycinnamate. A liquid vehicle base is then a remainder of the solution by weight. The composition is an artificial tear formulation or an ophthalmic suspension or ointment. The composition may include at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.

Abstract: The disclosure provides stable formulations of cationic biocides that are primarily used in the treatment and prevention of infections. The disclosure is also concerned with processes for forming stable emulsions of cationic biocides and petrolatum.

Abstract: Novel absorbable polymer blends are disclosed. The blends are useful for manufacturing medical devices having engineered degradation and breaking strength retention in vivo. The blends consist of a first absorbable polymeric component and a second absorbable polymeric component. The weight average molecular weight of the first polymeric component is higher than the weight average molecular weight of the second polymeric component. At least at least one of said components is at least partially end-capped by a carboxylic acid group. Further aspects are medical devices made therefrom.